 |
 |
 |
 |
 |
Treatment Name: |
 |
Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma |
 |
 |
 |
 |
Phase: |
 |
Phase 3 |
 |
 |
 |
 |
 |
 |
Treatment ID#: |
 |
1714 RTOG 05-25 |
 |
 |
 |
 |
Age Group: |
 |
Adult And Pediatric |
 |
 |
 |
 |
 |
 |
Min Karnofsky Score: |
 |
90: Able to perform normal activity; minor signs and symptoms of disease |
 |
 |
 |
 |
Conditions: |
 |
Prior Surgery is Allowed Prior Radiation is Not Allowed Prior Chemotherapy is Not Allowed |
 |
 |
 |
 |
 |
 |
Last Updated: |
 |
04/11/2008 |
 |
 |
 |
 |
Tumor Types: |
 |
Glioblastoma Multiforme |
 |
 |
 |
 |
 |
 |
 |
Comments: |
 |
The primary objective is to determine if increasing the "dose-density" of the adjuvant temozolomide component of the chemoradiation treatment enhances treatment efficacy as measured by overall survival.
|
 |
 |
 |
 |
 |
 |
Treatment Type: |
 |
Chemotherapy Radiation |
 |
 |
 |
 |
Contact: |
 |
Clinical Trials Office - Cancer Institute of New Jersey Cancer Institute of New Jersey at Cooper
Voorhees, NJ 08043 USA Phone: 856-325-6757 Fax: E-mail: Website: |
 |
 |